Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NASDAQ:CCOI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$228.94+0.1%$219.78$163.81▼$244.81$404.31B0.516.42 million shs2.24 million shsCCOICogent Communications$42.96-0.3%$39.25$29.61▼$86.76$2.11B0.77880,564 shs254,795 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-1.26%+1.00%+2.46%+19.76%+21.08%CCOICogent Communications-2.36%-4.41%+7.40%-11.79%-47.57%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$228.94+0.1%$219.78$163.81▼$244.81$404.31B0.516.42 million shs2.24 million shsCCOICogent Communications$42.96-0.3%$39.25$29.61▼$86.76$2.11B0.77880,564 shs254,795 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-1.26%+1.00%+2.46%+19.76%+21.08%CCOICogent Communications-2.36%-4.41%+7.40%-11.79%-47.57%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.74Moderate Buy$234.802.56% UpsideCCOICogent Communications 2.00Hold$46.608.47% UpsideCurrent Analyst Ratings BreakdownLatest ABBV and CCOI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/20/2025ABBVAbbVieGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$227.00 ➝ $242.0010/20/2025ABBVAbbVieGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$227.00 ➝ $242.0010/17/2025ABBVAbbVieRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$236.00 ➝ $250.0010/14/2025ABBVAbbVieErste Group BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold10/14/2025CCOICogent CommunicationsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell10/13/2025ABBVAbbVieCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral10/10/2025ABBVAbbViePiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$231.00 ➝ $284.0010/9/2025ABBVAbbVieCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$250.0010/8/2025ABBVAbbVieWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025CCOICogent CommunicationsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/3/2025ABBVAbbVieUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$251.00(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$56.33B7.18$14.77 per share15.50$1.90 per share120.50CCOICogent Communications$1.04B2.04$0.94 per share45.49$4.55 per share9.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.10108.9916.381.446.45%699.66%13.64%10/31/2025 (Estimated)CCOICogent Communications-$204.07M-$4.54N/AN/AN/A-21.57%-117.56%-6.78%11/6/2025 (Estimated)Latest ABBV and CCOI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025CCOICogent Communications-$1.15N/AN/AN/A$246.13 millionN/A10/31/2025Q3 2025ABBVAbbVie$3.26N/AN/AN/A$15.58 billionN/A8/7/2025Q2 2025CCOICogent Communications-$0.93-$1.21-$0.28-$1.21$247.79 million$246.25 million7/31/2025Q2 2025ABBVAbbVie$3.24$2.97-$0.27$0.52$14.93 billion$15.42 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.562.87%N/A312.38%53 YearsCCOICogent Communications$4.069.45%N/AN/A 14 YearsLatest ABBV and CCOI DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date9/5/2025ABBVAbbViequarterly$1.642.9%10/15/202510/15/202511/14/20258/6/2025CCOICogent Communicationsquarterly$1.01509.25%8/21/20258/21/20259/5/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie44.140.740.61CCOICogent Communications49.062.312.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%CCOICogent Communications92.45%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.25%CCOICogent Communications11.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie55,0001.77 billion1.76 billionOptionableCCOICogent Communications1,91649.18 million43.58 millionOptionableABBV and CCOI HeadlinesRecent News About These CompaniesCogent Communications to Host Third Quarter 2025 Earnings Call on November 6, 2025October 21 at 8:30 AM | prnewswire.comTriton Financial Group Inc Purchases Shares of 15,877 Cogent Communications Holdings, Inc. $CCOIOctober 21 at 6:04 AM | marketbeat.comMagnolia Group LLC Buys Shares of 1,093,211 Cogent Communications Holdings, Inc. $CCOIOctober 19, 2025 | marketbeat.comBrokerages Set Cogent Communications Holdings, Inc. (NASDAQ:CCOI) Price Target at $46.60October 19, 2025 | americanbankingnews.com5 Yields Up to 16% That Could Raise Their Payouts by New Year’s...October 16, 2025 | marketbeat.comCogent Communications (NASDAQ:CCOI) Downgraded to "Strong Sell" Rating by Zacks ResearchOctober 16, 2025 | marketbeat.comCogent Communications Holdings, Inc. (NASDAQ:CCOI) Receives Average Recommendation of "Hold" from AnalystsOctober 14, 2025 | marketbeat.comHow Investors May Respond To Cogent (CCOI) Cash Flow Pressures and Dilution RiskOctober 12, 2025 | finance.yahoo.comCogent Communications (CCOI): Assessing Valuation Following Reports of Financial Strain and Investor CautionOctober 12, 2025 | finance.yahoo.comBlair William & Co. IL Purchases 33,223 Shares of Cogent Communications Holdings, Inc. $CCOIOctober 11, 2025 | marketbeat.com1 Momentum Stock for Long-Term Investors and 2 Facing HeadwindsOctober 10, 2025 | finance.yahoo.comCogent Communications (NASDAQ:CCOI) Given "Sell (D)" Rating at Weiss RatingsOctober 9, 2025 | marketbeat.comCogent Comms (CCOI) Receives a Sell from Bank of America SecuritiesOctober 9, 2025 | theglobeandmail.comCogent Communications Holdings, Inc. $CCOI Shares Acquired by Herald Investment Management LtdOctober 6, 2025 | marketbeat.comDividend Growth Stocks: 5 Massive Yields That Could Rise Within WeeksOctober 5, 2025 | forbes.comCalculating The Intrinsic Value Of Cogent Communications Holdings, Inc. (NASDAQ:CCOI)October 4, 2025 | uk.finance.yahoo.comShould You Expect Great Results From Cogent Communications Holdings (CCOI)?October 3, 2025 | finance.yahoo.comCogent Communications Holdings, Inc. (CCOI): A Bull Case TheorySeptember 28, 2025 | finance.yahoo.comCogent Communications Holdings, Inc. (CCOI): A Bull Case Theory September 28, 2025 | insidermonkey.com1 Cash-Burning Stock for Long-Term Investors and 2 Facing ChallengesSeptember 23, 2025 | finance.yahoo.comMadison Small Cap Fund: Cogent Communications (CCOI) is Experiencing Early Growing PainsSeptember 18, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Datavault AI: The New AI Contender Backed by Big FundingBy Jeffrey Neal Johnson | October 1, 20253 Exceptional Stocks to Build Long-Term WealthBy Chris Markoch | October 6, 2025ABBV and CCOI Company DescriptionsAbbVie NYSE:ABBV$228.94 +0.26 (+0.11%) As of 01:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Cogent Communications NASDAQ:CCOI$42.96 -0.15 (-0.35%) As of 01:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cogent Communications Holdings, Inc., through its subsidiaries, provides high-speed Internet access, private network, and data center colocation space services in North America, Europe, Oceania, South America, and Africa. The company offers on-net Internet access and private network services to law firms, financial services firms, and advertising and marketing firms, as well as heath care providers, educational institutions and other professional services businesses, other Internet service providers, telephone companies, cable television companies, web hosting companies, media service providers, mobile phone operators, content delivery network companies, and commercial content and application service providers. It also provides Internet access and private network services to customers that are not located in buildings directly connected to its network; and on-net services to customers located in buildings that are physically connected to its network. In addition, the company offers off-net services to corporate customers using other carriers' circuits to provide the last mile portion of the link from the customers' premises to the network. Further, it operates data centers that allow its customers to collocate their equipment and access the network. It serves primarily to small and medium-sized businesses, communications service providers, and other bandwidth-intensive organizations. Cogent Communications Holdings, Inc. was founded in 1999 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys The Best AI for Picking Stocks, Ranked by Performance Will D-Wave's European Expansion Keep Fueling the Rally? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
